MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Начало・Списък с акции・Editas Medicine Inc

Editas Medicine Inc

Затворен

СекторЗдравеопазване

3.48 3.88

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.44

Максимум

3.52

Ключови измерители
By Trading Economics
Приходи	19M -5.6M
Продажби	17M 25M
EPS	-0.06
Марж на печалбата	-22.715
Служители	87
EBITDA	17M -5.3M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+104.01% upside

Дивиденти
By Dow Jones
Следващи печалби	11.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	87M 313M
Предишно отваряне	-0.4
Предишно затваряне	3.48

Настроения в новините

By Acuity

17%

83%

28 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.33 / 1.54 Подкрепа & съпротива

Editas Medicine Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.04.2026 г., 20:26 ч. UTC

Придобивния, сливания и поглъщания

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17.04.2026 г., 18:15 ч. UTC

Значими събития в новините

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17.04.2026 г., 16:49 ч. UTC

Значими събития в новините

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17.04.2026 г., 16:49 ч. UTC

Значими събития в новините

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17.04.2026 г., 22:58 ч. UTC

Печалби

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17.04.2026 г., 21:32 ч. UTC

Пазарно говорене

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17.04.2026 г., 21:22 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

17.04.2026 г., 21:22 ч. UTC

Пазарно говорене

Moody's Downgrades Belgium to A1 -- Market Talk

17.04.2026 г., 20:52 ч. UTC

Печалби

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

17.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

17.04.2026 г., 20:29 ч. UTC

Печалби

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17.04.2026 г., 20:11 ч. UTC

Придобивния, сливания и поглъщания

UCB to Buy Neurona Therapeutics for Up to $1.15B

17.04.2026 г., 19:34 ч. UTC

Пазарно говорене

Печалби

Придобивния, сливания и поглъщания

Global Equities Roundup: Market Talk

17.04.2026 г., 19:34 ч. UTC

Пазарно говорене

Печалби

Придобивния, сливания и поглъщания

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17.04.2026 г., 19:31 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17.04.2026 г., 19:26 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Edge Up -- Market Talk

17.04.2026 г., 19:21 ч. UTC

Пазарно говорене

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17.04.2026 г., 19:15 ч. UTC

Пазарно говорене

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17.04.2026 г., 19:07 ч. UTC

Пазарно говорене

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17.04.2026 г., 18:57 ч. UTC

Значими събития в новините

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17.04.2026 г., 18:53 ч. UTC

Придобивния, сливания и поглъщания

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17.04.2026 г., 18:53 ч. UTC

Придобивния, сливания и поглъщания

UCB 2026 Rev Guidance Unchanged

17.04.2026 г., 18:52 ч. UTC

Придобивния, сливания и поглъщания

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17.04.2026 г., 18:52 ч. UTC

Придобивния, сливания и поглъщания

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17.04.2026 г., 18:14 ч. UTC

Пазарно говорене

Значими събития в новините

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17.04.2026 г., 18:00 ч. UTC

Значими събития в новините

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17.04.2026 г., 18:00 ч. UTC

Значими събития в новините

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17.04.2026 г., 17:31 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17.04.2026 г., 17:26 ч. UTC

Пазарно говорене

Печалби

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Editas Medicine Inc Прогноза

Ценова цел

By TipRanks

104.01% нагоре

12-месечна прогноза

Среден 7.12 USD 104.01%

Висок 15 USD

Нисък 4 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Editas Medicine Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Editas Medicine Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.33 / 1.54Подкрепа & съпротива

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Настроение

By Acuity

28 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.